Changes and predictors of radiation-induced oral mucositis in patients with oral cavity cancer during active treatment
Changes and predictors of radiation-induced oral mucositis in patients with oral cavity cancer during active treatment
复制标题
DOI:
10.1016/j.ejon.2014.12.001
复制
发表时间:
2015-06-01
影响因子:
2.8
通讯作者:
Chang, Joseph Tung-Chien
中科院分区:
文献类型:
--
作者:
Chen, Shu-Ching;Lai, Yeur-Hur;Chang, Joseph Tung-Chien
Purpose: Radiation-induced oral mucositis (OM) is the most debilitating side effect of radiation treatment in oral cavity cancer. The purpose of the study was to investigate change of prevalence of severe OM, OM-related symptoms, and predictors in oral cavity cancer patients during active treatment.Methods and sample: Longitudinal study design with repeated measures was used. Patients with oral cavity cancer were recruited from a head and neck outpatient radiation department at a major medical center in Taiwan. Patients' OM-related symptoms were measured at three time points. Patients' oral mucosa was assessed at nine time points. Generalized estimating equations (GEE) were used to analyze the predictive factors of prevalence of severe OM and OM-related symptoms.Results: Patients reported highest prevalence of severe OM at T5 (5 weeks after beginning RT) and T6 (6 weeks after beginning radiation therapy, RI), with the combined chemotherapy and RT (CCRT) patients reporting a higher prevalence than those receiving RT alone. The peak of OM-related symptoms was at T8 (8 week after beginning RT), with primary symptoms of mouth pain, mouth dryness, eating difficulties, swallowing difficulties, and taste change. Patients with CCRT, a higher cumulative radiation dose, smoking, and lower body mass index (BMI) were at high risk to develop severe OM. OM-related symptoms were predicted by type of treatment, cumulative radiation dose, and smoking.Conclusions: Patients with oral cavity cancer suffer from OM and OM-related symptoms during aggressive RI or CCRT. Patient-specific oral care and emotional support are needed to relieve distressful OM-related symptoms during active treatment. (C) 2014 Elsevier Ltd. All rights reserved.